Initiate synthesis and testing of novel PET ligands and develop and test novel CSF/blood biomarkers for assessment of disease related pathological burdens such as tau, inflammation, synaptic dysfunction.
Development and testing of 3-5 novel PET ligands and/or CSF/blood biomarkers for assessment of AD and ADRD pathology.
2014 to 2018
Research Implementation Area
B. Diagnosis, Assessment and Disease Monitoring
Activities, Funding Initiatives, and Resources
NIH PA-06-017: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…
NIH PA-06-018: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…
NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer's Disease in Down Syndrome (R01)
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH RFA-AG-16-019: Limited Competition: Alzheimer's Disease Neuroimaging Initia…